Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Intermittent self-catheterisation in MS.
Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
B cells and multiple sclerosis.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Tcelna® (imilecleucel-T)
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Receptos reports third quarter 2013 financial results
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Change in the clinical development program for laquinimod
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
New York Academy of Sciences: T Cells at the Interface of Immune-CNS Cross-Talk

Pages